CD300a/LMIR1 Antibody (232618) [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: ELISA
• Clone: 232618
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 350

CD300a/LMIR1 Antibody (232618) [Alexa Fluor® 350] Summary

• Immunogen: Y3 rat myeloid cell line transfected with human CD300a/LMIR1
• Specificity: Detects human CD300a/LMIR1 in ELISA.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD300a/LMIR1 Antibody (232618) [Alexa Fluor® 350]

• CD300a antigenCMRF35H9
• CD300a molecule
• CD300a
• CLM8
• CLM-8
• CMRF35H leukocyte immunoglobulin-like receptor
• CMRF-35H
• CMRF35-H
• CMRF35-H9
• CMRF-35-H9CD300 antigen-like family member A
• CMRF35HIRp60
• CMRF35-like molecule 8
• IGSF12
• IGSF12NK inhibitory receptor
• Immunoglobulin superfamily member 12
• Inhibitory receptor protein 60
• IRC1
• IRC1/IRC2
• IRC2
• IRp60
• leukocyte membrane antigen
• LMIR1
• MAIR-I
• Mcipr1
• NKRL
• Pigr4

Background

CD300a, also known as LMIR1 (in rodents), CMRF-35H, IRp60, CLM-8, and MAIR-I, is a 60 kDa glycoprotein member of the immunoglobulin superfamily (1). Human CD300a consists of a 163 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane segment, and a 98 aa cytoplasmic domain that contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and a non-canonical ITIM (2). Alternative splicing may generate additional isoforms that either lack the Ig-like domain or contain only the cytoplasmic domain. Within the ECD, human CD300a shares 40% and 43% aa sequence identity with mouse and rat LMIR1, respectively. In human, CD300a is expressed on peripheral blood eosinophils, mast cells, neutrophils, plasmacytoid dendritic cells, and various T cell subsets (3‑7). Antibody crosslinking of CD300a induces phosphorylation of tyrosine residues in the cytoplasmic domain. This leads to the recruitment of phosphatases SHIP, SHP-1, and SHP-2 and inhibition of NK cell, eosinophil, and mast cell activation (2, 3, 5‑7). Crosslinking of CD300a to other surface proteins such as SCF R or Fc epsilon RI on mast cells, Fc gamma RIIA on neutrophils, or CCR3 on mast cells and eosinophils inhibits downstream signaling from those receptors (5, 10‑12). CD300a crosslinking also limits the in vivo activities of these cells with a subsequent reduction of allergic inflammation symptoms (4, 11, 12).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.